Market research
SMMT Summit Therapeutics PLC
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 10B
- P/E ratio
- Not available
- Analyst target
- 28.6279
- Dividend yield
- Not available
- Beta
- -1.24
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US86627T1088
- Market cap
- 10B
- P/E ratio
- Not available
- Analyst target
- 28.6279
- Dividend yield
- Not available
- Beta
- -1.24
About
About Summit Therapeutics PLC
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy, which is in phase III clinical trial for the patients with epidermal growth factor receptor, mutated, and locally advanced or metastatic non-squamous NSCLC; first-line metastatic NSCLC; and first-line unresectable metastatic CRC. It markets its products in the United states, Canada, Europe, Japan, Latin America, Middle East, and Africa. The company was founded in 2003 and is headquartered in Miami, Florida.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the SMMT discussion.
5 years, 4 months ago
Summit Therapeutics Inc is currently in a long term uptrend where the price is trading 32.2% above its 200 day moving average.
From a valuation standpoint, the stock is 61.1% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 521.4.
Summit Therapeutics Inc's total revenue rose by 128.8% to $366K since the same quarter in the previous year.
Its net income has increased by 99.7% to $-29K since the same quarter in the previous year.
Finally, its free cash flow fell by 270.7% to $-23M since the same quarter in the previous year.
Based on the above factors, Summit Therapeutics Inc gets an overall score of 4/5.